ライフサイエンスコーパス: mucosal infection

1 protective mechanisms, especially following mucosal infection.

2 vector-borne transmission to study T. cruzi mucosal infection.

3 ty may display differential activity against mucosal infection.

4 soluble CD154 (CD40L) concomitant with their mucosal infection.

5 ibody can play an important role in clearing mucosal infection.

6 cells and are avirulent in animal models of mucosal infection.

7 HIV/Simian Immunodeficiency Virus (SIV) oral mucosal infection.

8 responses associated with protection against mucosal infection.

9 st genital HSV-2 disease but did not prevent mucosal infection.

10 eased risk of HIV-1 transmission at sites of mucosal infection.

11 CCR5 and CXCR4 together inhibited localized mucosal infection.

12 isease with either virus but did not prevent mucosal infection.

13 urrent disease in guinea pigs that developed mucosal infection.

14 munodeficiency virus (HIV and SIV) following mucosal infection.

15 ere significantly protected against T. cruzi mucosal infection.

16 on and the ensuing immune response following mucosal infection.

17 ells/microL, irrespective of the presence of mucosal infection.

18 ll be influenced strongly by the presence of mucosal infection.

19 ee strains of immunocompetent mice supported mucosal infections.

20 tical step in the pathogenesis of chlamydial mucosal infections.

21 erapy to treat microbial keratitis and other mucosal infections.

22 smission by reducing viral extinction during mucosal infections.

23 birth, leading to a higher susceptibility to mucosal infections.

24 veloping effective vaccines against skin and mucosal infections.

25 nstrating the importance of fungal burden in mucosal infections.

26 ects in innate immunity associated with such mucosal infections.

27 H. influenzae causes predominantly mucosal infections.

28 protection from H. pylori and possibly other mucosal infections.

29 vaccines are available for the prevention of mucosal infections.

30 , and has broad applicability for a study of mucosal infections.

31 e is a major cause of otitis media and other mucosal infections.

32 an increased rate, severity, and duration of mucosal infections.

33 es to provide competitive advantage in human mucosal infections.

34 critical antiviral effectors in hepatic and mucosal infections.

35 ent vulvovaginal candidiasis (VVC), a common mucosal infection affecting significant numbers of women

36 zi is a protozoan parasite that can initiate mucosal infection after conjunctival exposure.

37 e study of protective immunity to chlamydial mucosal infection and for the identification of chlamydi

38 s of strain-specific differences in reovirus mucosal infection and systemic dissemination have enhanc

39 hat can be used to study the pathogenesis of mucosal infection and to evaluate the efficacy of vaccin

40 nding facilitates our understanding of HIV-1 mucosal infection and will benefit the development of st

41 set and activity of IgAN often coincide with mucosal infections and dysregulation of cytokines, we hy

42 hogen of humans, can cause both debilitating mucosal infections and fatal invasive infections.

43 impairs host defense mechanisms that control mucosal infections and inhibits the mechanisms that cont

44 ber of the mucosal microbiota, but can cause mucosal infections and life-threatening disseminated inv

45 ungal pathogen of humans causing superficial mucosal infections and life-threatening systemic disease

46 portunistic fungal pathogen that causes both mucosal infections and life-threatening systemic infecti

47 athogen in humans, causing both debilitating mucosal infections and potentially life-threatening syst

48 ector CD8 T cell response, both systemic and mucosal infection are equally effective in the different

49 ays in which these cells help defend against mucosal infection are only beginning to be understood.

50 nd the resulting increased susceptibility to mucosal infection are poorly understood.

51 , and episodes of gross haematuria following mucosal infections are common; 30% of patients develop p

52 well as alters fungal morphology in a mouse mucosal infection assay.

53 at IL-22 provides a mechanistic link between mucosal infection, B-cell recruitment, and humoral autoi

54 poptosis is important in the pathogenesis of mucosal infections but has not been studied with H. pylo

55 tic view of host-pathogen interaction during mucosal infection, but also allow deeper insight into th

56 ding of the host-pathogen interactome during mucosal infection by a bacterial pathogen.

57 IL-17RA-mediated responses in the control of mucosal infection by Brucella.

58 plays the more important role in initiating mucosal infection by HIV-1.

59 tative approaches to enhance protection from mucosal infection by improving immune defenses at the mu

60 ermine the role of IgA in protection against mucosal infection by influenza and the value of immuniza

61 significantly protects rhesus macaques from mucosal infection by the highly pathogenic strain SIVmac

62 ide the first direct evidence that transient mucosal infection can induce SIV-specific immunity that

63 aginal candidiasis (VVC) is an opportunistic mucosal infection caused by Candida albicans that affect

64 Vulvovaginal candidiasis (VVC) is a common mucosal infection caused by Candida species in women of

65 n vivo IL-17-dependent responses during oral mucosal infections caused by the human commensal fungus

66 To examine the consequences of mucosal infection for the T cell response to orally admi

67 the ideal model system should resemble human mucosal infection if vaccine design is to be effective.

68 tion in 5.9%, typhoid fever in 3.7%, skin or mucosal infection in 1.5%, and meningitis in 0.2%.

69 In the current study, we examined mucosal infection in several immunocompetent and immunoc

70 Influenza is a highly contagious mucosal infection in the respiratory tract.

71 Therefore, resistance to mucosal infection in these monkeys may not be mediated b

72 er may be responsible for protection against mucosal infection in this population of monkeys.

73 mia, neutrophil functions, and opportunistic mucosal infections in HIV.

74 to the immunotherapeutic prevention of other mucosal infections in humans and animals.

75 ex formation and disease exacerbation during mucosal infections in IgAN patients.

76 on than HSV-2 as a cause of oral and genital mucosal infections in young women, but there are importa

77 tions for understanding host defense against mucosal infections, including the pathogenesis of these

78 Preceding mucosal infection induces mucosal immunity, resulting in

79 it is unclear to what degree systemic versus mucosal infection influences the generation of effector

80 Protection against mucosal infection is therefore achievable by parenteral

81 ystem perceives commensals in the context of mucosal infection is unclear.

82 The primary immunologic defense against many mucosal infections is IgA.

83 M) cells that accumulate in tissue following mucosal infection may be crucial for long-term immunity.

84 and HIV-1, and thus validate the SIV-macaque mucosal infection model for HIV-1 vaccine and microbicid

85 ency in cultured murine cells or in a murine mucosal infection model.

86 tion of lung and trachea sections, show that mucosal infection of guinea pigs is an efficient model f

87 Here, the authors show that oropharyngeal mucosal infection of macaques with a high ZIKV dose resu

88 address these we have used a model of local mucosal infection of mice with reovirus.

89 Here, we show that during acute mucosal infection of mice with Toxoplasma gondii, inflam

90 5alpha genotype does not confound results of mucosal infection of rhesus macaques with SIV(mac251).

91 vival of apparently self-limited and luminal mucosal infections requires a systemic T cell-dependent

92 i.v. route was not recapitulated following a mucosal infection route.

93 philus influenzae (NTHi) is a major cause of mucosal infections such as otitis media, sinusitis, conj

94 icit systemic immunity that protects against mucosal infections, such as the vaccines for influenza a

95 T-cell responses are important in combating mucosal infections, the generation of such immune respon

96 s, causing diseases ranging from superficial mucosal infections to disseminated, systemic infections

97 n immunocompromised hosts, ranging from mild mucosal infections to lethal disseminated disease.

98 virus-specific antibody secretion following mucosal infection were a direct result of pDC-derived ty

99 systemic immune systems and protects against mucosal infection with a virus expressing HIV-1 gp160.

100 We hypothesized that protection against mucosal infection with F. tularensis would be significan

101 mined the importance of monocytes in primary mucosal infection with herpes simplex virus 2 (HSV-2), a

102 es using a physiologically relevant model of mucosal infection with herpes simplex virus type 2.

103 s (CTLs) and protect rhesus macaques against mucosal infection with simian/human immunodeficiency vir

104 A (IgA) has been implicated in resistance to mucosal infections with bacteria, viruses, and parasites

105 ncluding four macaques who controlled rectal mucosal infection without progressive systemic dissemina